Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mannose - AUG Therapeutics

Next Previous
Search
Drug Profile

Mannose - AUG Therapeutics

Alternative Names: AVTX 802; CERC 802; D-Mannose - AUG Therapeutics

Latest Information Update: 02 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ichorion Therapeutics
  • Developer Avalo Therapeutics; Ichorion Therapeutics
  • Class Hexoses; Monosaccharides; Small molecules
  • Mechanism of Action Mannose replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn error metabolic disorders
  • New Molecular Entity No

Highest Development Phases

  • Suspended Inborn error metabolic disorders

Most Recent Events

  • 31 Oct 2023 AUG Therapeutics acquires Mannose from Avalo Therapeutics
  • 02 Mar 2022 Suspended - Phase-I for Inborn error metabolic disorders (In volunteers) in USA (PO), due to challenges with study feasibility
  • 02 Mar 2022 Suspended - Phase-II for Inborn error metabolic disorders (PO), due to challenges with study feasibility

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top